OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Mar 2, 2023 • 23min
S8 Ep24: Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple Myeloma
Dr Jakubowiak discusses interim findings from the ATLAS trial of KRd vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.
Feb 27, 2023 • 6min
S8 Ep23: FDA Approval Insights: Pirtobrutinib in MCL
Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.
Feb 23, 2023 • 17min
S8 Ep22: Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
Dr Mascarenhas discusses established standards of care and ongoing research with JAK inhibitors in patients with myelofibrosis; the available frontline treatment options in this disease; and the nuances of myelofibrosis treatment sequencing.
Feb 16, 2023 • 14min
S8 Ep21: FDA Approval Insights: Zanubrutinib in CLL and SLL
Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Feb 13, 2023 • 15min
S8 Ep20: Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies
Drs Short and Reagan discuss risk factors that can contribute to patients’ likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.
Feb 9, 2023 • 10min
S8 Ep19: D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.
Feb 6, 2023 • 10min
S8 Ep19: FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
Dr Strickler discusses the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer, key efficacy and safety findings from the MOUNTAINEER trial, and ongoing research seeking to address remaining unmet needs in this population.
Feb 2, 2023 • 14min
S8 Ep18: Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.
Jan 30, 2023 • 11min
S8 Ep17: Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.
Jan 26, 2023 • 13min
S8 Ep17: FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.
